Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Alceus Bio awarded Pioneer Group and AbbVie’s Golden Ticket

Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.

The initiative is designed to support breakthrough scientific discovery with the potential to advance human health and accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.

Bionow BioAI Summit 2026

Bridging Life Sciences and Artificial Intelligence 

AI is rapidly reshaping the life sciences sector, from accelerating drug discovery to transforming diagnostics and personalising treatment pathways. The 2026 Bionow BioAI Summit brings together experts from industry, academia and healthcare to explore how AI is being applied across the sector and where it can deliver the most impact. Join us to connect and share insight around the future of AI. 

York and North Yorkshire Life Sciences Forum

Connecting Innovation, Talent and Opportunity in the Heart of the North 

Join us for the inaugural York and North Yorkshire Life Sciences Forum, a new event bringing together leading health and life sciences businesses, academic innovators, investors and policymakers to shape the future of the sector in one of the UK's most promising emerging clusters, as part of the York and North Yorkshire Health and Life Sciences Cluster Mobilisation Project. 

About the event 

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s

Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.

Coulter Partners places Chief Executive Officer at Alethio Therapeutics

LONDON, UK  – January 7, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.

Subscribe to